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ABSTRACT
Background: BRAFV600E mutation is present in a subset of pediatric brain tumors. 
Vemurafenib is an oral, selective ATP-competitive inhibitor of BRAFV600E kinase. The 
goal of this multi-center study conducted through the Pacific Pediatric Neuro-Oncology 
Consortium (PNOC) was to determine the recommended phase 2 dose (RP2D) and 
dose limiting toxicities (DLTs) in children < 18 years with recurrent or progressive 
BRAFV600E mutant brain tumors.
Results: Nineteen eligible patients were enrolled. Eleven patients had received 
three or more prior therapies. Data reported are from the start of treatment for 
the first patient (April 30 2014) through August 31 2019. The RP2D was defined 
as 550 mg/m2 twice daily after DLT criteria adjustment for rash. Related grade ≥ 3 
adverse events included secondary keratoacanthoma (n = 1); rash (n =16); and fever  
(n = 5). Subjects received a median of 23 cycles (range 3–63). Four patients remain 
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on treatment. Centrally reviewed best radiographic responses included 1 complete 
response, 5 partial responses, and 13 stable disease. The steady-state area under the 
curve (AUC0-∞median) was 604 mg*h/L (range 329–1052).
Methods: Vemurafenib was given starting at 550 mg/m2, twice daily which 
corresponds to the adult RP2D. Adverse events were graded using the NIH Common 
Terminology Criteria for Adverse Events (CTCAE) version 4.0. Central imaging review 
was performed. Pharmacokinetic sampling was performed.
Conclusions: Vemurafenib has promising anti-tumor activity in recurrent BRAF 
V600E-positive brain tumors with manageable toxicity. A phase 2 study is ongoing 
(NCT01748149).
INTRODUCTION
BRAFV600E is one of the most common oncogenic 
mutations in human tumors, found in 50% of metastatic 
melanomas, 10% of metastatic colon carcinomas, and 
30% of papillary thyroid carcinomas [1]. This point 
mutation results in a constitutively active form of BRAF 
that functions as a monomer and is resistant to feedback 
inhibition [2]. Small molecule inhibitors that specifically 
target the BRAFV600E kinase domain have been developed 
and have shown significant, albeit transient, activity in 
adult metastatic melanomas with BRAFV600E mutations 
[3]. An unexpected side effect of this class of inhibitors 
is a high risk of secondary squamous cell carcinoma 
(keratoacanthoma). These occur in approximately 25% 
of treated adults and have been demonstrated to contain 
activating RAS mutations (or less frequently NOTCH 
or TGF deletions) and show growth stimulation through 
paradoxical activation of wild type RAF dimers by BRAF 
inhibitors [4].
Gliomas are the most common subgroup of pediatric 
brain tumors [5]. Children with low grade gliomas (WHO 
grade 1 and 2) have an excellent prognosis when these 
lesions can be totally resected, but often require adjuvant 
therapy when gross total resection cannot be achieved. 
Children with high grade gliomas (WHO grade 3 and 4) 
have a poor prognosis, despite aggressive multimodal 
therapy and no standard therapy, other than surgical 
resection and radiotherapy, has been established [6].
Until recently, adjuvant treatment for children 
with gliomas was limited to cytotoxic chemotherapy and 
radiation due to the lack of knowledge of the biological 
drivers of these tumors and a lack of available agents 
that could target such drivers [7]. Over the past ten 
years, many groups have demonstrated a high frequency 
of alterations in the RAS/RAF/MAPK pathway in 
pediatric gliomas. BRAFV600E mutations, in particular, 
are found in 5% of malignant astrocytomas, 9% of 
pilocytic astrocytomas, 50% of gangliogliomas and 
66% of pleomorphic xanthoastrocytomas [8]. Our group 
demonstrated significant anti-tumor efficacy of PLX4720 
(tool compound analog of the BRAFV600E-specific inhibitor 
vemurafenib) in intracranial xenografts harboring 
BRAFV600E-mutant gliomas, while showing no efficacy 
against BRAF-wild type xenografts [9].
Herein we report on a multi-center phase 1 study 
conducted through the Pacific Pediatric Neuro-Oncology 
Consortium (PNOC) of vemurafenib in children < 18 
years of age with recurrent or progressive BRAFV600E 
mutant brain tumors. At the time of trial development, 
there were no published reports of vemurafenib safety, 
efficacy, CNS penetration or pharmacokinetics in children 
with gliomas.
RESULTS
Subject characteristics
Among 19 eligible patients, one was not compliant 
with medications during the DLT period and therefore not 
fully evaluable for estimation of RP2D or PK analysis. 
Table 1 summarizes the subject characteristics. The most 
common histology was pilocytic astrocytoma (n=10). 
Although this trial was open to both low and high-grade 
tumors, only patients with low-grade tumors enrolled in 
the safety study. While this trial was open at multiple sites, 
the relative scarcity of pediatric patients with recurrent 
BRAFV600E mutant brain tumors led to expected relatively 
slow accrual.
Toxicities
The most common toxicity was maculopapular rash 
(Table 2). This is a known side effect of vemurafenib and 
responded well to holding the drug and supportive care. 
Two of the three patients initially treated at both Dose 
Level 0 and −1 had grade 3 rash and met DLT criteria. 
As these rashes resolved shortly after holding drug 
with appropriate supportive care and did not recur with 
restarting drug, we subsequently amended the study to 
exclude rash that resolved within 7 days with supportive 
care as a DLT. As a consequence, rather than further dose 
reductions, additional patients were treated at dose level 
−1. Dose level −1 was subsequently declared safe without 
further rash and patients were then escalated back up 
to dose level 0, which was also well tolerated and was 
determined as the RP2D.
One thirteen-year-old patient developed several 
facial lesions during Cycle 4 that were tissue confirmed 
squamous cell carcinoma (SCC).
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Table 1: Patient characteristics
Age in years, at study enrollment, median (min, max) 9 (3–17)
Number of courses of vemurafenib: median (min, max) 23 (4–64)
Number of Prior Therapies Number of patients
One 4
Two 4
Three or more 11
Number Percentage
Gender
Males 9 47.4
Females 10 52.6
Race
White, non-Hispanic 14 73.7
Black 2 10.5
Unknown 3 15.8
Diagnosis
Astrocytoma (NOS) 1 5.3
Fibrillary Astrocytoma 1 5.3
Pilocytic Astrocytoma 10 52.6
Ganglioglioma 5 26.3
Pleomorphic Xanthoastrocytoma 2 10.5
Table 2: Number of grade 2 & 3 toxicities probably, possibly or definitely attributable to vemurafenib
Adverse Event Grade 2 Grade 3
Alanine aminotransferase increased 0 1
Alkaline phosphatase increased 1 1
Alopecia 1 0
Anorexia 2 0
Arthralgia 3 0
Aspartate aminotransferase increased 2 0
Blood bilirubin increased 3 1
Bullous dermatitis 1 0
Creatinine increased 2 0
Diarrhea 2 0
Dry skin 3 0
Electrocardiogram QT corrected interval prolonged 0 1
Erythema multiforme 1 0
Erythroderma 1 0
Fatigue 2 0
Fever 1 2
Gastrointestinal disorders - Acid reflux 1 0
Headache 1 0
Hypertension 2 0
Hypophosphatemia 1 0
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Pharmacokinetics
A total of 19 subjects underwent pharmacokinetic 
sampling. One subject with poor compliance was 
removed from the final analysis. The steady-state AUC0-
∞ median was 604 mg*h/L (range 329–1052 mg*h/L). 
Pharmacokinetic analysis demonstrated a significant 
accumulation factor (approximately six-fold) over time 
with each vemurafenib dose. In an attempt to correlate 
exposure with response, patients were divided into those 
having stable disease (SD) versus those having PR or CR. 
Patients with SD had 11% lower AUCss (586 mg*hr/L) 
compared to PR+CR (657 mg*hr/L). However, a logistic 
regression model using AUCs as a predictor of PR+CR 
was not significant given the observed variability.
Patient outcomes
Patient outcomes are reported for the 19 patients 
treated. The median number of vemurafenib courses was 
23 (range 3 to 63). Centrally reviewed best radiographic 
responses included 1 CR, 5 PR, and 13 patients with 
SD (Figure 1). Solid tumor component was measured 
for determination of outcomes in 10 patients, with 
the remaining 9 patients with no measurable solid 
component undergoing measurement of solid/cystic 
Investigations - Plantar hyperkeratosis with pain 1 0
Lymphocyte count decreased 2 1
Mucositis oral 1 0
Nausea 1 0
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - keratoacanthomas 0 1
Palmar-plantar erythrodysesthesia syndrome 1 0
Photosensitivity 0 1
Pneumonitis 0 1
Pruritus 1 1
Rash maculo-papular 12 10
Skin and subcutaneous tissue disorders – Dermatitis, heat rash, photoonycholysis 3 0
Skin infection 1 0
Somnolence 1 0
Weight loss 1 0
Figure 1: Depicted is the centrally reviewed “best response” per patient, based on the maximum change compared 
to on study MRI. Each bar represents a patient. Grey bars depict patients treated on dose level 0 and red bars show subjects treated on 
dose level-1.
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lesion for outcome determination. Figure 1 demonstrates 
best response percent decrease in tumor size during 
the course of treatment with vemurafenib. As shown 
in Table 3, responses were durable with some patients 
having continuous response for over 40 months. Cystic 
lesions appeared to decrease more in size compared to 
the solid lesions with vemurafenib therapy (Table 4). 
Interestingly, we found that 10 of the patients in our 
cohort who presented with contrast-enhancing tumors 
were found to develop loss of enhancement during 
treatment. Examples of radiographic responses are shown 
in Figure 2, with representative solid, cystic, and mixed 
solid/cystic lesions.
Of the 19 patients, only one patient (patient 10) 
progressed on therapy (Table 3). Three patients (patients 
1,3, and 6) came off drug because they had completed 
therapy (originally defined as 12 months). Eleven patients 
came off drug due to adverse events or patient decision. 
Four patients remain on therapy. Of the fourteen patients 
total that came off drug without progressive disease, only 
four progressed during the 12-month protocol-defined 
follow up period (Table 3).
DISCUSSION
The discovery of BRAFV600E mutations in a wide 
spectrum of gliomas has led to optimism that these tumors 
can be therapeutically targeted by potent inhibitors of 
the mutant form of BRAF developed for the treatment of 
melanoma. Herein, we report that vemurafenib is safe in 
children with BRAFV600E gliomas and has promising anti-
tumor efficacy.
Vemurafenib was approved for the treatment of 
BRAF-mutant melanoma in 2011. Toxicities in adults 
with melanoma include rash, arthralgias and secondary 
malignancies (mostly SCC) [3]. The latter are of particular 
concern when considering this therapeutic approach for 
children, particularly for low grade tumors. In this phase 
1 study, we found that the adult dose equivalent of 550 
mg/m2 was well tolerated in children with a similar 
safety profile seen in adult subjects. These results are 
similar to the small study of vemurafenib in adolescents 
with melanoma [10] and the recently reported pediatric 
experience with Langerhans Cell Histiocytosis [11]. While 
we encountered rash as a DLT in our initial cohort of 
patients, this was not seen once we amended our protocol 
with more universally used criteria for grading transient 
grade 3 non-hematologic toxicities in patients receiving 
BRAF inhibitors. Interestingly, one patient developed SCC 
while on vemurafenib therapy in our study. This patient did 
not have any concerning lesions at baseline and developed 
facial SCC during cycle 4 of therapy. Biopsy confirmed 
the diagnosis and genomic analysis of the SCC revealed 
TGF-beta receptor homozygous deletions, without any 
additional mutations affecting the RASA/RAF/MAPK 
pathway. TGF-beta signaling is known to have a tumor 
suppressive effect in skin stem cells and loss of TGF-beta 
signaling has been associated with SCC development 
in adults treated with BRAF inhibitors [4]. Of note, one 
of the six adolescents treated with vemurafenib in the 
melanoma study also developed an SCC [10].
Only one of the 19 patients who participated in this 
phase 1 study developed progression while on therapy. 
Four patients remain on therapy with a mean of > 23 
cycles of therapy. Our study found a high proportion of 
objective radiographic responses that were durable, 
with 1 CR, 5 PRs, and 13 SDs as the centrally-reviewed 
best responses on therapy. The recently reported phase 
I/IIa experience with the BRAFV600E inhibitor dabrafenib 
in children with recurrent pediatric low grade glioma 
reported 1 CR, 13 PR, 11 SD and two progressive diseases 
as best responses in a cohort of 32 patients [12, 13]. This 
is of particular interest as both drugs have been shown to 
have poor CNS penetration in animal models [14]. It is 
important to point out that the dabrafenib study used the 
RANO criteria [15] to measure objective response, while 
our study used a modified RANO criteria which included 
tumor cysts in measurements.
One of the pressing issues facing the pediatric 
neuro-oncology community is the optimal duration of 
therapy for targeted agents. Of our fourteen patients that 
halted treatment for either toxicity, patient decision, or 
completion of therapy, four patients progressed during 
12 months of follow up (Table 3). This suggests that 
while responses can be durable in some patients after 
halting drug, the ideal duration of therapy remains to 
be determined. Of note, three of our four patients that 
developed progressive disease off drug progressed within 
four months of stopping therapy and so careful early 
monitoring of patients who stop vemurafenib therapy is 
warranted.
The first reported trial of a BRAF inhibitor 
(sorafenib) for pediatric gliomas did not report any 
secondary skin cancer formation, but instead reported a 
significant stimulation of glioma tumor growth, which 
we did not observe in our cohort [16]. The underlying 
etiology of the sorafenib growth activation was thought to 
be the presence of the KIAA1549: BRAF fusion protein 
in the majority of enrolled patients. In contrast, our 
study restricted eligibility to patients with the BRAFV600E 
mutation and specifically excluded patients with the 
KIAA1549: BRAF fusion, NF1, or any other known 
RAS-opathy. Appropriate subject selection and detailed 
preclinical characterization will be critical as targeted 
therapies such as vemurafenib will be integrated in the 
care of these children.
Pharmacokinetic analyses revealed similar drug 
exposure and kinetics as in adult patients [17]. It is well 
recognized there are often differences in pharmacodynamic 
endpoints between pediatrics and adults. Limitations exist 
when adult PK data and study endpoints are applied to a 
pediatric population particularly in early phase trials where 
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Table 3: Patient Outcomes
Patient ID-
Pathology1
Enrolled 
Dose  
(mg/m2)
On 
treatment 
date
Off 
treatment 
date2
Dose 
Limiting 
Toxicity
Best 
Response3
Number 
of cycles4
Reason Off 
Treatment5
Date of 
progression
1 - low grade 
astrocytoma NOS 550 4/30/2014 5/27/2015 yes PR 14
Completed 
Therapy 9/1/2015
3 - pilocytic 
astrocytoma 550 9/29/2014 9/2/2015 no SD 12
Completed 
Therapy n/a
4 - pilocytic 
astrocytoma 550 10/16/2014 + yes SD 64 n/a n/a
5 - PXA 420 12/4/2014 8/13/2015 yes SD 9 Adverse event n/a
6 - fibrillary 
astrocytoma 420 1/29/2015 12/28/2015 no SD 12
Completed 
Therapy n/a
7 - pilocytic 
astrocytoma 420 3/9/2015 5/31/2016 yes SD 16
Patient 
decision* n/a
10 - 
ganglioglioma 420 8/20/2015 9/15/2016 no SD 14
Disease 
progression 9/13/2016
11 - pilocytic 
astrocytoma 420 9/30/2015 2/13/2019 no SD 44
Patient 
decision* n/a
12 - ganglioglioma 420 12/8/2015 2/11/2019 no SD 41 Patient decision* 4/19/2019
13 - pilocytic 
astrocytoma 420 12/31/2015 4/8/2016 no PR 4 Adverse event n/a
14- pilocytic 
astrocytoma 420 4/14/2016 5/17/2018 no SD 27
Patient 
decision* n/a
15 -ganglioglioma 420 5/12/2016 + no SD 43 n/a n/a
16 - 
ganglioglioma 420 6/15/2016 + no SD 42 n/a n/a
17 -pilocytic 
astrocytoma 550 9/29/2016 + no PR 38 n/a n/a
18 - PXA 550 10/3/2016 8/8/2018 no CR 24 Patient decision* n/a
19 - pilocytic 
astrocytoma 550 11/10/2016 8/31/2018 no SD 24
Patient 
decision* n/a
20 - pilocytic 
astrocytoma 550 1/11/2017 10/26/2018 no PR 23 Adverse event 12/11/2018
21 - pilocytic 
astrocytoma 550 2/22/2017 4/25/2018 no PR 15 Adverse event 12/10/2018
22- ganglioglioma 550 2/21/2017 11/8/2018 no SD 22 Poor compliance n/a
1. NOS = not otherwise specified; PXA = Pleomorphic Xanthoastrocytoma
2. + Indicates that the patient remains on treatment as of 8/31/2019
3. Best response by imaging. PR = partial response; SD = stable disease
4. Median number of cycles = 23
5. Completion of protocol is defined as completing 12 cycles therapy.
*Patient decision to stop treatment with stable disease after 12 or more cycles; treatment was allowed to continue 
indefinitely as long as no toxicity, progression, or patient preference
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likelihood of success is low. Additionally, the historically 
applied maximum tolerated dose (based on toxicity) is 
often not equivalent to the maximum efficacious dose 
(based on biomarkers). Given the lack of data for reliable 
biomarkers in this rare disease population we specifically 
designed the study collection of new data (both PK and 
biomarkers) so that it can be combined with future trials 
to enhance sample size and better defining exposure-
response relationships to optimize the use of this drug in 
the pediatric population. While there was a correlation 
between drug exposure and radiographic response, this 
was not statistically significant in this cohort. Within the 
phase 2 study that is actively ongoing we will also assess 
if crushing vemurafenib for liquid formulation leads to 
similar exposure which is an important assessment when 
developing therapeutic options for children.
In summary, we report that vemurafenib is tolerable 
and efficacious in children with recurrent low grade gliomas 
Figure 2: Depicted are representative images of subjects treated on PNOC-002 demonstrating. (A) regression of a contrast 
enhancing cystic lesion on a contrast, T1 weighted MR image over time; (B) regression of a solid/cystic lesion on a T2 weighted MR image 
over time; (C) regression of a contrast enhancing solid lesion on a contrast, T1 weighted MR image over time.
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with BRAFV600E mutations. The RP2D is 550 mg/m2 
twice daily. An efficacy cohort in patients under 25 years 
of age has recently completed accrual at the RP2D and 
will be reported separately once data matures. The upper 
age limit of the efficacy trial was extended to 25 years 
to accelerate our accrual due to the overall rarity of the 
disease being studied.
MATERIALS AND METHODS
Eligibility
The study was reviewed and approved by the 
Institutional Review Board of each participating institution. 
Verbal and written informed consent was obtained from 
all participants or their parents with assent obtained for 
the appropriately aged patients. Patients under 18 years 
of age who had a histologically confirmed diagnosis of 
a BRAFV600E-mutant primary brain tumor and Lansky 
or Karnofsky performance score ≥ 60 were eligible. 
Confirmation of the BRAFV600E mutation was required 
in a CLIA-approved laboratory, either by sequencing or 
immunohistochemistry. Either fresh biopsy or archival 
tissue were allowable for genotyping. Subjects must have 
had disease that failed at least one prior therapy (including 
radiation or systemic therapy) besides surgery and had to 
have evidence of measurable disease on MRI. There was 
no restriction for number of prior therapies. Subjects must 
have recovered from acute side effects of prior therapies and 
shown evidence of adequate bone marrow function (absolute 
neutrophil count > 1000 cells/ul, hemoglobin > 8 gm/dl and 
platelets > 75,000/ul), renal function within normal limits for 
age and liver function (total bilirubin < 1.5 × ULN for age, 
ALT and AST < 2.5 × ULN for age). Corticosteroids had to 
be on a stable or decreasing dose prior to treatment. The QTc 
on pre-treatment EKG had to be < 450 msec. Patients must 
have been able to swallow tablets.
Children with active lesions suspicious for 
keratoacanthoma or cutaneous squamous cell carcinoma 
were excluded as were subjects with a known diagnosis 
of Neurofibromatosis Type 1 or any other RAS-opathy 
due to risk of paradoxical activation of tumor growth [18]. 
Further, prior exposure to a BRAF inhibitor constituted an 
exclusion criteria.
Table 4: Patients listed by their study numbers and shown are product of bi-dimensional tumor measurements for 
each tumor lesion. Some patients had more than one lesion
Patient # Cystic Solid/Cystic Solid Central review Best Response
1  −93 −79 PR
3 −78 −37  SD
4   −11 SD
5  −24  SD
6 −12 7  SD
7 −73  −29 SD
10 −89 −39  SD
11   −45 SD
12  −32 −16 SD
13  −77  PR
14  −3  SD
15   −46 SD
16 −92 −100 −31 SD
17 −100 −80  PR
18   −100 CR
19   −34 SD
20  −82 −54 PR
21 −72 −64  PR
22  −39  SD
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Treatment regimen, administration, and dose 
escalation design
Vemurafenib (RO5185426; PLX4032) was supplied 
in 120 mg and 240 mg tablets by Genentech, Roche. Study 
drug was administered orally twice daily (BID) in 28-
day cycles. Doses were adjusted based on body surface 
area (m2) prior to each cycle. The starting dose level 
(dose level 0) was 550 mg/m2 BID twice daily which was 
equivalent to the adult recommended phase 2 dose (RP2D) 
of 960 mg based upon an average adult BSA of 1.73 m2. 
The maximum dose administered in this trial was capped 
at 960 mg BID. Planned de-escalation dose levels included 
dose level -1 420 mg/m2, dose level -2 330 mg/m2, dose 
level -3 240 mg/m2 BID on a 28-day cycle and dose level 
-4 240 mg/m2 day 1–7 and 15–21. Dosing nomograms were 
used to accommodate the available pill sizes. Dose levels 
-1 and -2 were only considered for study subjects if the 
body surface area (BSA) was greater than 0.75 m2 and dose 
level -3 and -4 only when BSA was greater than 0.9 m2.
Definition of dose limiting toxicity (DLT)
Toxicities were graded based on the NCI Common 
Terminology Criteria for Adverse Events (CTCAE) version 
4.0. Dose limiting toxicities (DLT) were based on adverse 
events occurring in the first 28 day cycle. Hematologic 
DLT was defined as any treatment related grade 4 
hematologic toxicity with the exception of lymphopenia 
and anemia, grade 3 neutropenia with fever; or grade 3 
thrombocytopenia. Non-hematologic DLTs were initially 
defined as any grade 3 or 4 related non-hematologic toxicity. 
The protocol was subsequently amended to exclude grade 
3 rash, diarrhea, infection, fever, or photosensitivity that 
resolved to grade ≤ 2 within 7 days of appropriate medical 
management in the DLT definition. This was based on 
additional Genentech/Roche trial experience supporting that 
these specific side effects can be well managed and should 
not constitute a DLT. Any related grade 2 non-hematological 
toxicity that persisted for more than 7 days and was 
considered sufficiently medically significant or sufficiently 
intolerable by patients to warrant treatment interruption and/
or dose reduction was also considered dose-limiting.
Definition of response
Disease evaluation was by MR imaging on 1.5T or 
3T clinical scanner that occurred at baseline followed by 
every 2-months assessments. Standard clinical sequences 
included 3 plane localizer, axial T2 weighted imaging, 
3D fluid attenuated inversion recovery (FLAIR), and 
T1 weighted imaging without and with intravenous 
gadolinium. Subjects had the option to switch to every 
3 months assessment after cycle 24. All images were 
anonymized prior to a retrospective central review by 
a study assigned neuroradiologist. Response criteria 
used were a modified version of the published “RANO” 
criteria [15]. Given that tumor cysts are commonly found 
in low grade gliomas in children, these were not excluded 
from measurements, as noted below. Measurable disease 
was defined as lesions that can be accurately measured 
in two dimensions with a minimum size of no less than 
double the slice thickness. T2 FLAIR sequences were 
used for disease assessment. All tumor measurements were 
recorded in millimeters or decimal fractions of centimeters 
and expressed as sum of products of largest diameter and 
perpendicular diameter. Tumor measurements over time 
were performed side by side in single session to maintain 
corresponding plane of view. Many of the lesions had 
both solid and cystic components. Tumor measurements 
included measurement of a solid portion of the tumor 
in lesions where the solid portion could be measured in 
isolation. In tumors with multiple cystic components 
that were inseparable from solid component, combined 
measurement of the “solid/cystic” lesion was performed. 
In tumors with only measurable cystic component, 
measurement of the cyst was performed. Previously 
irradiated lesions were considered non-measurable except 
in cases of documented progression of the lesion since the 
completion of radiation therapy. Complete response (CR) 
was defined as complete disappearance of the target lesion 
and no new lesions; partial response (PR) was defined as > 
50% tumor reduction in product of bi-dimensional tumor 
measurements of solid lesions. Progressive disease (PD) 
was defined as an increase in product of bi-dimensional 
tumor measurements > 25% in a solid lesion or the 
appearance of a new lesion. For confirmation of CR and 
PR, results needed to be sustained for 8 weeks.
Pharmacokinetics
Pharmacokinetic sampling
Serial blood samples for PK were collected on days 
1, 15 and 22 in cycle one of vemurafenib treatment. Whole 
blood samples were collected at 2, 4, 8, and 24 hours post-
dose on day 1 with additional trough levels obtained 
just prior to (t = 0) and 1-hour post dose on days 15. PK 
collection was then repeated on day 22 with samples 
collected just prior to (t = 0) and 2, 4, 8, and 24 hours 
post-dose. Two milliliters of blood was collected at each 
sampling time through a venous catheter and placed in a 
heparinized tube for vemurafenib analysis. All samples, 
within 30 minutes of collection, were centrifuged at 
3400 rpm for 10 minutes at 4° C, and the plasma removed 
and stored at –80° C until analysis.
Bioanalysis
Plasma samples were analyzed by Covance Inc. 
(Princeton, New Jersey) using a validated reverse phase 
high performance liquid chromatography with mass 
spectrometry. The assay was linear in the range of 25.0 
to 50,000 ng/ml RO5185426 (vemurafenib, PLX4032). 
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Samples with concentrations above the upper limit of 
linearity were diluted and re-assayed. Samples with 
vemurafenib levels reported below the lower limit of 
quantification (LLOQ) were entered into the PK analysis 
as half the value of the LLOQ. Assay accuracy, intra-
day, and inter-day variability ranged from 90.4–105.9%, 
1.0–7.3%, and 1.8–6.1%, respectively.
Pharmacokinetic analysis
A nonlinear mixed effects modeling approach was 
used to describe vemurafenib time-plasma concentration 
data. A recent publication from the same authors described 
the population pharmacokinetic analysis in detail [19]. The 
non-linear mixed effect modeling approach has been used 
for characterizing the population pharmacokinetics in the 
past half-century [20]. Briefly, a one-compartment model 
with first-order absorption and elimination was applied, 
with a bodyweight-based allometric component added 
to all clearance and volume parameters using a fixed 
exponent of 0.75 and 1, respectively. Between-occasion 
variability was included in the final covariate model using 
an exponential equation. The area-under-the-curve (AUC) 
for each patient was derived from the empirical Bayes 
estimate of individual clearance (CL) (AUC = Dose/CL).
Statistical design
Due to the relative scarcity of BRAFV600E-mutant 
recurrent pediatric brain tumors and the expected 
difficulty in accrual for a traditional dose-escalation 
study, this study was conducted to determine the safety of 
the adult RP2D equivalent of 960 mg BID (based on the 
average adult size of 1.73 m2), namely 550 mg/m2/dose 
BID (dose level 0).
Three patients were initially enrolled at the dose 
level 0 and observed for toxicity during the dose-finding 
period (cycle 1). The dose escalation and de-escalation 
followed a modified 3+3 design as follows: if more than 
1 DLT occurred in the first 3 patients at dose level 0, that 
dose was declared intolerable and subsequent patients 
were enrolled into the lower dose cohorts described earlier. 
If, on the other hand, 1 or fewer DLTs were observed at 
dose level 0, 3 additional patients were enrolled into that 
dose. Barring excessive toxicity, accrual to any dose level 
would be complete once 6 patients had been treated, and 
no more than 1 patient in a cohort of 6 experienced a 
DLT. There were 4 lower dose levels allowed, and dose 
escalation beyond dose level 0 was not allowed.
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